Atomwise develops artificial intelligence systems for drug discovery. Its groundbreaking research technology learns like a human chemist, using powerful deep neural networks and supercomputers to analyze millions of potential medicines each day. Atomwise deploys its discovery platform to predict both new and repurposed drug candidates for pharmaceutical companies, biotechnology startups and research institutions. The system uses a specialized algorithm to run through millions of molecular structures in order to pin down the most likely combination for certain diseases. Atomwise co-founder Alex Levy has explained in the past that the system uses a neural network to come up with new ways of approaching the data, just like a brain might. Labs can take that information and begin testing compounds with newly discovered materials in order to find a cure.